Real-world effectiveness of fluticasone propionate-azelastine nasal spray in moderate-to-severe nonallergic and perennial allergic rhinitis.

Authors

Piyaporn Chokevittaya, Noraworn Jirattikanwong, Phanu Prasankiattirach, Chamard Wongsa, Norapat Limsirorat, Pasiri Jungsanguanpornsuk, Mongkhon Sompornrattanaphan, Kawita Atipas, Navarat Kasemsuk, Dichapong Kanjanawasee, Triphoom Suwanwech, Pongsakorn Tantilipikorn, Wannada Laisuan, Phichayut Phinyo, Jonathan A Bernstein, Torpong Thongngarm

Published in

The World Allergy Organization journal. Volume 19. Issue 9. Pages 101461. Epub Sep 08, 2026.

Abstract

Although combined intranasal corticosteroid-antihistamine sprays are approved for allergic rhinitis, evidence supporting their effectiveness in nonallergic rhinitis (NAR) remains limited.
To compare the treatment response to fluticasone propionate-azelastine (FP-Aze) for treating NAR and perennial allergic rhinitis (PAR).
This prospective observational real-world study enrolled adults with moderate-to-severe PAR or NAR. Participants received FP-Aze nasal spray (50/137 μg), 1 spray per nostril twice daily for 4 weeks. The primary endpoint was the change from baseline in the visual analog scale (VAS) for rhinitis, ranging from 0 to 100 mm. Treatment effectiveness in NAR was assessed for noninferiority, with a prespecified margin of 23 mm on the VAS relative to PAR. Secondary outcomes included evaluation of non-nasal symptoms and quality of life (QoL).
Patients with moderate-to-severe PAR (n = 108) and NAR (n = 62) were included. FP-Aze significantly improved nasal symptoms in both groups. At Week 4, adjusted mean changes (95% CI) in VAS for rhinitis were -52.20 mm (-57.37, -47.03) in PAR and -48.59 mm (-55.64, -41.54) in NAR. The between-group difference in mean change was 3.61 mm (-5.58, 12.79), meeting the noninferiority criterion. QoL improved significantly in both groups, with no significant between-group differences. Sensitivity analyses excluding patients who used as-needed oral antihistamines yielded consistent results. Treatment was well tolerated, with a bitter taste as the most commonly reported adverse event; no serious adverse events were observed.
The effectiveness of FP-Aze in moderate-to-severe NAR was noninferior to PAR on the VAS for rhinitis, supporting its use in this population. These findings help address an important evidence gap, as data supporting FP-Aze in NAR remain limited.

PMID:
42741242
Bibliographic data and abstract were imported from PubMed on 15 Sep 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.